

DEA Approves Study of MDMA-Assisted Psychotherapy for Anxiety Associated with Life-Threatening Illness

On Friday, March 13, the U.S. Drug Enforcement Administration approved our study of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness, led by Principal Investigator Phil Wolfson, M.D., in Marin, California (*pictured, right*). This will be the first clinical trial of MDMA-assisted psychotherapy for this indication. This study is now screening and enrolling subjects.

\$587,000 estimated study cost • \$176,000 raised
\$411,000 still needed



Treatments Begin in Canadian Study of MDMA-Assisted Psychotherapy for PTSD

On March 14, 2015, the third subject received their first experimental treatment in our Canadian study of MDMA-assisted psychotherapy for PTSD. Led by Principal Investigator Ingrid Pacey, M.D., in Vancouver, B.C., this Phase 2 study will treat up to 12 subjects with chronic, treatment-resistant PTSD from any cause. This is the first Health Canada-approved clinical psychedelic research to take place in over 40 years. "After suffering under the drug war paradigm for decades, the current change toward an evidence-based approach to psychedelics is both refreshing and illuminating," says MAPS Canada Board of Directors chair Mark Haden (*pictured, left*).

\$419,000 estimated study cost • \$51,000 raised + \$3,500 raised by partners
\$364,500 still needed

Colorado Awards MAPS \$2 Million for Medical Marijuana Study

On December 17, 2014, the Colorado Department of Public Health and Environment awarded MAPS a \$2 million grant, fully funding our planned study of marijuana for PTSD in 76 U.S. veterans. This is the first public funding that MAPS has ever received in our 28½ year history. We are now waiting to receive marijuana from the National Institute on Drug Abuse (NIDA), the sole supplier of marijuana for federally regulated research in the U.S.

Principal Investigator Sue Sisley, M.D., was honored with the Americans for Safe Access (ASA) Researcher of the Year Award at the National Medical Marijuana Unity Conference in Washington, D.C., on March 30, 2015 (*pictured, right*).



MAPS
Public Benefit
Corporation

MAPS Announces Formation of New Public Benefit Corporation

MAPS is proud to announce the formation of the MAPS Public Benefit Corporation (MPBC), a new wholly owned subsidiary of MAPS. The special purpose of MPBC is to serve as a vehicle for conducting MAPS' research, and to balance social benefits with income from the legal prescription sale of MDMA, other psychedelics, and marijuana. *See the full story on page 4.*

THE
NEW YORKER

Michael Pollan Writes for *The New Yorker* about Psychedelic Research

Acclaimed journalist Michael Pollan's article in *The New Yorker* covers the resurgence of psychedelic science, highlighting current clinical research into the benefits of psychedelic-assisted psychotherapy for medical, spiritual, and personal growth purposes. "The Trip Treatment," published on February 9, 2015, features interviews with leading researchers and study participants.

Credit: Illustration by Stephen Doyle



MAPS Receives \$82,766 Award as one of reddit's Top 10 Charities

On February 26, 2015, the community news website reddit awarded \$82,765.95 to MAPS and nine other non-profit organizations chosen by the reddit community. We express our profound appreciation to reddit and the reddit community for supporting psychedelic and medical marijuana research and education. Join the conversation at maps.org/reddit.